Market
Will GametoGen's iPSC technology be used in over 1000 IVF procedures by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Reports from GametoGen or industry publications
Story
GametoGen Achieves First Live Birth Using iPSC Technology in IVF, Reducing Hormone Injections by 80% and Treatment to Three Days
Dec 16, 2024, 04:09 PM
GametoGen, a next-generation IVF startup, has announced the first successful live birth using its innovative technology, which utilizes induced pluripotent stem cell (iPSC)-derived ovarian cells. This groundbreaking achievement marks a significant milestone in reproductive technology, as the company claims it is the first human birth resulting from iPSC technology. The new method reportedly replaces 80% of the hormone injections typically required in traditional IVF and shortens treatment cycles to just three days. The announcement has garnered attention for its potential to revolutionize access to IVF and improve outcomes for families seeking fertility assistance.
View original story
Similar markets
Cancer Therapy • 25%
Anti-Aging Treatments • 25%
Regenerative Medicine • 25%
Other • 25%
No • 50%
Yes • 50%
5 to 10 • 25%
More than 20 • 25%
11 to 20 • 25%
Less than 5 • 25%
6-10 • 25%
More than 20 • 25%
0-5 • 25%
11-20 • 25%
Moderate Improvement • 25%
Significant Improvement • 25%
No Improvement • 25%
Harmful Effects • 25%
Yes • 50%
No • 50%
More than 50 labs • 25%
20-30 labs • 25%
41-50 labs • 25%
31-40 labs • 25%
1-3 • 25%
10 or more • 25%
7-9 • 25%
4-6 • 25%
More than 20 transplants • 25%
0-5 transplants • 25%
6-10 transplants • 25%
11-20 transplants • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
